The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Research Report 2024
Synopsis
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market was valued at US$ 14380 million in 2023 and is anticipated to reach US$ 56720 million by 2030, witnessing a CAGR of 21.4% during the forecast period 2024-2030.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
Report Scope
The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Segment by Type
CellSearch
Others
Segment by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Circulating tumor cells (CTCs) are tumor cells that detach from the primary tumor and travel in the bloodstream, spreading from the original tumor to other locations, leading to cancer metastasis. These cells exist in peripheral blood of cancer patients and detection of CTCs can help to determine the process of metastasis. In contrast with other blood cells, the number of CTCs is very rare in blood which makes them difficult to detect.
Cancer stem cells (CSCs) are cancer cells that have all the classical properties of normal stem cells. Specifically, they are able to both give rise to more copies of themselves and to give rise to all cell types found in the cancer.
The global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market was valued at US$ 14380 million in 2023 and is anticipated to reach US$ 56720 million by 2030, witnessing a CAGR of 21.4% during the forecast period 2024-2030.
The major players in global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market include Janssen, Qiagen, Advanced Cell Diagnostics, etc. North America and Europe are main markets, they occupy about 65% of the global market. CellSearch is the main type, with a share about 70%. Breast Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment are main applications, which hold a share about 60%.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs).
Report Scope
The Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Janssen
Qiagen
Advanced Cell Diagnostics
ApoCell
Biofluidica
Clearbridge Biomedics
CytoTrack
Celsee
Fluxion
Gilupi
Cynvenio
On-chip
YZY Bio
BioView
Fluidigm
Ikonisys
AdnaGen
IVDiagnostics
Miltenyi Biotec
ScreenCell
Silicon Biosystems
Segment by Type
CellSearch
Others
Segment by Application
Breast Cancer Diagnosis and Treatment
Prostate Cancer Diagnosis and Treatment
Colorectal Cancer Diagnosis and Treatment
Lung Cancer Diagnosis and Treatment
Other Cancers Diagnosis and Treatment
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 CellSearch
1.2.3 Others
1.3 Market by Application
1.3.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Breast Cancer Diagnosis and Treatment
1.3.3 Prostate Cancer Diagnosis and Treatment
1.3.4 Colorectal Cancer Diagnosis and Treatment
1.3.5 Lung Cancer Diagnosis and Treatment
1.3.6 Other Cancers Diagnosis and Treatment
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Perspective (2019-2030)
2.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Growth Trends by Region
2.2.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Region (2019-2024)
2.2.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Region (2025-2030)
2.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Dynamics
2.3.1 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Industry Trends
2.3.2 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Drivers
2.3.3 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Challenges
2.3.4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players by Revenue
3.1.1 Global Top Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Players by Revenue (2019-2024)
3.1.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue Market Share by Players (2019-2024)
3.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue
3.4 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Ratio
3.4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Revenue in 2023
3.5 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Key Players Head office and Area Served
3.6 Key Players Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Product Solution and Service
3.7 Date of Enter into Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Breakdown Data by Type
4.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Type (2019-2024)
4.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Type (2025-2030)
5 Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Breakdown Data by Application
5.1 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Historic Market Size by Application (2019-2024)
5.2 Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
6.2 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2019-2024)
6.4 North America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
7.2 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2019-2024)
7.4 Europe Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
8.2 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2019-2024)
8.4 Asia-Pacific Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
9.2 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2019-2024)
9.4 Latin America Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size (2019-2030)
10.2 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2019-2024)
10.4 Middle East & Africa Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Janssen
11.1.1 Janssen Company Detail
11.1.2 Janssen Business Overview
11.1.3 Janssen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.1.4 Janssen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.1.5 Janssen Recent Development
11.2 Qiagen
11.2.1 Qiagen Company Detail
11.2.2 Qiagen Business Overview
11.2.3 Qiagen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.2.4 Qiagen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.2.5 Qiagen Recent Development
11.3 Advanced Cell Diagnostics
11.3.1 Advanced Cell Diagnostics Company Detail
11.3.2 Advanced Cell Diagnostics Business Overview
11.3.3 Advanced Cell Diagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.3.4 Advanced Cell Diagnostics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.3.5 Advanced Cell Diagnostics Recent Development
11.4 ApoCell
11.4.1 ApoCell Company Detail
11.4.2 ApoCell Business Overview
11.4.3 ApoCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.4.4 ApoCell Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.4.5 ApoCell Recent Development
11.5 Biofluidica
11.5.1 Biofluidica Company Detail
11.5.2 Biofluidica Business Overview
11.5.3 Biofluidica Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.5.4 Biofluidica Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.5.5 Biofluidica Recent Development
11.6 Clearbridge Biomedics
11.6.1 Clearbridge Biomedics Company Detail
11.6.2 Clearbridge Biomedics Business Overview
11.6.3 Clearbridge Biomedics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.6.4 Clearbridge Biomedics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.6.5 Clearbridge Biomedics Recent Development
11.7 CytoTrack
11.7.1 CytoTrack Company Detail
11.7.2 CytoTrack Business Overview
11.7.3 CytoTrack Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.7.4 CytoTrack Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.7.5 CytoTrack Recent Development
11.8 Celsee
11.8.1 Celsee Company Detail
11.8.2 Celsee Business Overview
11.8.3 Celsee Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.8.4 Celsee Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.8.5 Celsee Recent Development
11.9 Fluxion
11.9.1 Fluxion Company Detail
11.9.2 Fluxion Business Overview
11.9.3 Fluxion Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.9.4 Fluxion Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.9.5 Fluxion Recent Development
11.10 Gilupi
11.10.1 Gilupi Company Detail
11.10.2 Gilupi Business Overview
11.10.3 Gilupi Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.10.4 Gilupi Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.10.5 Gilupi Recent Development
11.11 Cynvenio
11.11.1 Cynvenio Company Detail
11.11.2 Cynvenio Business Overview
11.11.3 Cynvenio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.11.4 Cynvenio Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.11.5 Cynvenio Recent Development
11.12 On-chip
11.12.1 On-chip Company Detail
11.12.2 On-chip Business Overview
11.12.3 On-chip Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.12.4 On-chip Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.12.5 On-chip Recent Development
11.13 YZY Bio
11.13.1 YZY Bio Company Detail
11.13.2 YZY Bio Business Overview
11.13.3 YZY Bio Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.13.4 YZY Bio Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.13.5 YZY Bio Recent Development
11.14 BioView
11.14.1 BioView Company Detail
11.14.2 BioView Business Overview
11.14.3 BioView Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.14.4 BioView Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.14.5 BioView Recent Development
11.15 Fluidigm
11.15.1 Fluidigm Company Detail
11.15.2 Fluidigm Business Overview
11.15.3 Fluidigm Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.15.4 Fluidigm Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.15.5 Fluidigm Recent Development
11.16 Ikonisys
11.16.1 Ikonisys Company Detail
11.16.2 Ikonisys Business Overview
11.16.3 Ikonisys Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.16.4 Ikonisys Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.16.5 Ikonisys Recent Development
11.17 AdnaGen
11.17.1 AdnaGen Company Detail
11.17.2 AdnaGen Business Overview
11.17.3 AdnaGen Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.17.4 AdnaGen Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.17.5 AdnaGen Recent Development
11.18 IVDiagnostics
11.18.1 IVDiagnostics Company Detail
11.18.2 IVDiagnostics Business Overview
11.18.3 IVDiagnostics Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.18.4 IVDiagnostics Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.18.5 IVDiagnostics Recent Development
11.19 Miltenyi Biotec
11.19.1 Miltenyi Biotec Company Detail
11.19.2 Miltenyi Biotec Business Overview
11.19.3 Miltenyi Biotec Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.19.4 Miltenyi Biotec Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.19.5 Miltenyi Biotec Recent Development
11.20 ScreenCell
11.20.1 ScreenCell Company Detail
11.20.2 ScreenCell Business Overview
11.20.3 ScreenCell Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.20.4 ScreenCell Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.20.5 ScreenCell Recent Development
11.21 Silicon Biosystems
11.21.1 Silicon Biosystems Company Detail
11.21.2 Silicon Biosystems Business Overview
11.21.3 Silicon Biosystems Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Introduction
11.21.4 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Business (2019-2024)
11.21.5 Silicon Biosystems Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
